Melanotan II vs MGF
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Melanotan II
Melanotan II (MT-II) is a cyclic lactam analog of alpha-melanocyte stimulating hormone (α-MSH) that acts as a potent, non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R). Developed at the University of Arizona in the late 1980s, it produces eumelanin-driven skin darkening (tanning) via MC1R, sexual arousal and spontaneous erections via MC4R, and appetite suppression via MC3R/MC4R. Bremelanotide (PT-141) — now FDA-approved for female sexual dysfunction — was derived from Melanotan II.
Full profileMGF
MGF (Mechano Growth Factor) is a splice variant of IGF-1 produced locally in muscle tissue in response to mechanical loading (exercise, especially eccentric loading). Unlike circulating IGF-1 which is produced primarily by the liver, MGF is generated within the muscle itself and acts locally to activate satellite cells (muscle stem cells) — the cells responsible for muscle repair, growth, and adaptation. It is considered the primary local anabolic signal generated by resistance training.
Full profile| Melanotan II | MGF | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | MT-II, MTII, Cyclo[Nle4,D-Phe7]-α-MSH | Mechano Growth Factor, IGF-1Ec, Insulin-like Growth Factor splice variant |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 250mcg–1000mcg mcg, Daily during loading phase; 2–3x weekly for maintenance | 100mcg–300mcg mcg, Post-workout (within 30–60 minutes of training), 3–4x weekly |
| Administration | Subcutaneous injection (most common), Intranasal (less effective, lower bioavailability) | Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution) |
| Key side effects | Nausea (most common — especially first 30–60 minutes post-injection), Facial flushing, Spontaneous erections (males — often unwanted at higher doses), Fatigue / yawning post-injection | Localized muscle swelling at injection site (normal response), Hypoglycemia (less pronounced than IGF-1 DES but present), Very short half-life means side effects are brief, Potential overuse injury if post-workout injection is used consistently without adequate recovery |
| Cited sources | 3 references | 3 references |
Key differences
- Evidence level differs: Melanotan II is research-stage, while MGF is preclinical only.
- Administration: Melanotan II — Subcutaneous injection (most common), Intranasal (less effective, lower bioavailability); MGF — Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution).
- Frequency: Melanotan II is typically Daily during loading phase; 2–3x weekly for maintenance; MGF is Post-workout (within 30–60 minutes of training), 3–4x weekly.
How each works
Melanotan II
Melanotan II's broad melanocortin receptor agonism produces a constellation of effects across multiple systems. MC1R activation in melanocytes upregulates tyrosinase, the rate-limiting enzyme in melanin synthesis, producing UV-independent skin darkening. MC4R activation in the CNS and spinal cord drives sexual arousal and erectogenic effects more potent than most PDE5 inhibitors, and also produces appetite suppression and reduced food intake (the same pathway exploited by weight-loss drugs targeting the melanocortin system). MC3R activation contributes to energy homeostasis effects.
MGF
MGF is encoded by the IGF-1 gene but produced via alternative splicing that generates a unique 49-amino acid C-terminal E-peptide (Ec peptide). The Ec peptide has distinct biological activity from the IGF-1 domain — it directly activates satellite cell proliferation through a receptor pathway separate from the standard IGF-1R. Studies in rodents show that local MGF injection produces significant muscle hypertrophy in the injected limb without systemic IGF-1 elevation. MGF expression spikes within 30 minutes of resistance exercise and declines over 24–48 hours — aligning precisely with the post-exercise anabolic window.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.